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Summary 
Rheumatoid  arthritis is a multistep disorder  associated with autoimmune features of yet un- 
known etiology. Implication of viruses such as Epstein-Barr virus (EBV) in rheumatoid arthritis 
pathogenesis has been suspected on the basis of several indirect observations, but thus far, a di- 
rect link between EBV and rheumatoid arthritis has not been provided. Here we show that a 
large fraction of T  cells infiltrating affected joints from a patient with chronic rheumatoid ar- 
thritis recognizes two EBV transactivators (BZLF1  and BMLF1) in a major histocompatibility 
complex-restricted fashion.  Responses to these EBV antigens by synovial lymphocytes from 
several other chronic rheumatoid  arthritis panents were readily detectable.  Thus these results 
suggest a direct contribution of EBV to chronic rheumatoid arthritis pathogenesis. They also 
demonstrate for the first  time the  occurrence of T  cell responses against EBV transactivating 
factors, which might be central in the control of virus reactivation. 
R 
heumatoid arthritis (RA) 1 is an incapacitating disease 
characterized by chronic joint inflammation and pro- 
gressive  destruction  of articular  structures,  which  affects 
about 1% of the population worldwide (1).  Its etiology re- 
mains unresolved, but there is ample evidence that T  cells 
contribute  directly to RA pathogenesis.  This is supported 
in particular by (a) the widespread T  cell infiltration of af- 
fected synovial membranes from RA patients  (2),  (b)  the 
genetic predisposition of RA, which is associated with cer- 
tain MHC  class II haplotypes (3-7),  and  (c) the beneficial 
effects ofT cell-depleting treatments in RA patients (8, 9). 
Despite this, the specificity of T  cells infiltrating RA lesions 
and their pathogenicity at late stages of the disease remain 
obscure.  With  respect  to  the  first  issue,  several candidate 
antigens  recognized  by  synovial  T  cells  have  been  pro- 
posed.  For instance,  a pathogenic role of T  cell-mediated 
immune responses against connective tissue proteins such as 
type II collagen Is supported by the occurrence of increased 
proliferative  responses  to  these  Ag  of synovial T  cells  as 
compared to PBL in R.A patients (10,  11). Besides endoge- 
nous compounds, several arthritogenic Ag ofmycobacterial 
IAbbreviations used in this paper: BLC, B lymphoblastoid  cells; RA, rheu- 
marred arthritis; SFL, synovlal fluid lymphocytes; SML, synovial mem- 
brane-derived lymphocytes. 
origin,  such  as  stress  proteins,  have been  shown  to  elicit 
synovial T  cell responses in some RA patients, although the 
importance  of stress  proteins in  synovial T  cell-mediated 
responses  against  mycobactena still  remains  controversial 
(12-15).  Furthermore,  a variety of viruses have been pro- 
posed as  RA  causative  agents  (1).  In particular,  EBV  has 
long been linked to RA on theoretical grounds  (e.g.,  be- 
cause  of the  existence  of shared  epitopes  between  EBV 
proteins  and  RA  autoantigens)  and  from  clinical  studies 
suggesting in particular increased anti-EBV serological re- 
sponses in a fraction of RA patients (16,  17).  However the 
physiopathological  relevance  of these  observations  is  still 
unclear, particularly because no evidence for anti-EBV re- 
sponses  within  RA  lesions  have  been  provided  thus  far. 
The pathogenicity of T  cells  at late stages of RA is also a 
controversial issue.  On  the  one  hand,  both the  extensive 
diversity of the  TCRs expressed by synovial lymphocytes 
isolated from most chronic RA patients  (18)  and the  evi- 
dence  for joint  destruction  and/or  active synovitis in  the 
absence of local lymphoid infiltrate in animal models and in 
humans  (19)  argues against a major role  of T  cells  in the 
perpetuation  of RA.  On  the  other  hand,  a  specific  Ag- 
driven T  cell recruitement to the joints at late stages of RA 
is indirectly supported by studies demonstrating oligoclonal 
T  cell expansions within the affected joints of several chronic 
RA patients (18). 
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Volume 184  November 1996 1791-1800 Table 1.  TCR Features, Frequency, and HLA Restriction of  Autologous BLC-reactive Syuovial  T  Cell Clones Derived from Chronic RA 
Patients  I and 19 
TCK BVBJ  CD1L3 [3  Percentage  Percentage  HLA 
T cell clone  composition  length (aa)  of SFL*  of PBL*  restriction 
Patient 1 
A2.10  BV2BJ1S2  8  5.6  <0.2  A*0201 
A2.19  BV2BJ2S3  8  1.5  <0.2  B'4002 
A2.3  BV2BJ2S7  8  4.0  <0.2  B'4002 
A2.8  BV2BJ2S7  8  4.0  <0.2  B'4002 
A2.1  BV2BJ2S7  8  4.0  <0.2  B'4002 
A2.21  BV2BJIS3  9  <0.2  <0.2  B'4002 
A2.4  BV2BJ2S5  10  2.0  <0.2  B'4002 
A14.11  BV14BJ2S7  9  <0.2  <0.2  B'4002 
A14.7  BV14BJ2S3  11  8.8  <0.2  B'4002 
A22.28  BV22BJ2S1  8  1.5  <0.2  B'4002 
A22.19  BV22BJ2S2  8  1.3  <0.2  B'4002 
A22.13  BV22BJ2S7  8  1.0  <0.2  B'4002 
A22.32  BV22BJ2S7  9  <0.2  <0.2  B'4002 
A22.34  BV22BJ2S2  12  <0.2  <0.2  B'4002 
A22.18  BV22BJ2S3  12  <0.2  <0.2  B'4002 
A17.10  BV17BJ2S3  8  0.3  <0.2  Cw*0102 
A17.11  BV17BJ2S4  8  0.4  <0.2  C*0102 
Patient 19 
B1  ND  ND  ND  ND  A'2401 
B2  ND  ND  ND  ND  B'3501 
B3  ND  ND  ND  ND  B'3501 
B4  ND  ND  ND  ND  B'3501 
All T cell clones listed in this table expressed distinct TCRs as demonstrated byjunctlonal sequence analysis (20). 
The T cell clones hsted here represented 19 of 20 V[32  +, 5 ofl0 V[314  +, 4 of 7 V[317  +, and 14 of 14 V[322  + CD8 + T cell colonies Isolated from pa- 
tient 1 SFL and 4 of 12 CD8 + T cell colonies isolated from patient 19 (20). 
*Percentage of SFL or PBL expressing TCR-[3 chains with the same VJ combination and the same length as that of the reactive T cell clone, esn- 
mated by semiquantitative PCR analysis (20). 
In  an  attempt  to  evaluate  the  repertoire  diversity  and 
specificity of T  cells activated during chronic RA, we re- 
cently studied the specificity ofsynovial T  lymphocytes de- 
rived from patients with  typical long lasting chronic  RA. 
Because in several patients the majority of synovial T  cells 
were CD8 +, both CD4 + ceils, which presumably comprise 
T  cells reactive against RA susceptibility HLA class II alleles, 
and CD8 + cells were analyzed. CD4 + and/or CD8 + syno- 
vial T  cell responses towards autologous and/or allogeneic 
B  lymphoblastoid cells (BLC) expressing one or several au- 
tologous HLA alleles were  detected m  four of six patients 
studied  (David-Ameline, J.,  M.A.  Peyrat,  and M.  Bonne- 
ville, unpublished results). Furthermore, in two patients, an 
enrichment for autologous BLC-reactive cells among syno- 
vial T  cells was  evidenced by comparative analyses of pa- 
tients' PBL and synovial T  cells (20; results summarized in 
Table 1). Together, these results suggested frequent expan- 
sions of cells reactive against autologous BLC during chronic 
RA.  Here we make use of this material to characterize by 
an expression cloning approach the antigens recognized by 
synovial T  cells derived from these patients. A  dominant re- 
sponse of synovial T  cells to two EBV transactivators is dem- 
onstrated, thus suggesting an Ag-driven recruitment ofT  cells 
to  the  synovium  in  these  patients  and  a  possible role  of 
these  EBV-specific  T  cells  in  chronic  RA  pathogenesis. 
More generally, this study provides the first clear-cut evi- 
dence  for T  cell responses against EBV  proteins playing a 
key function during virus replication. Such responses might 
have a  central role in the control of virus spreading under 
physiological and pathological situations. 
Materials and Methods 
Patients 
Patient  1  (HLA-A*0201/02,-B'2705/4002,-Cw*0102/15, 
DRBI*0101/0401,  DQBl*0301/0501)  had a typical erosive R.A 
lasting for 6 yr at the time of the first sample collection. He ful- 
filled six of seven criteria for RA defined by Arnett et al.  (21). 
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This patient received low-dose predmsone (7-12 mg/d) through- 
out. Synovlal fluid lymphocytes (SFL) were obtained during syno- 
vial fluid analysis before steroid infiltrations. Synov]al membrane 
lymphocytes (SML)  were obtained dunng surgery, performed 27 
mo after collection of SFL. All other patients fulfilled at least four 
out of seven critena for RA (21). Antx-EBV serology was studied 
in patients 1,  5,  and 6. All had serum antibodies against at least 
one of the following EBV proteins: RA nuclear antigen, Epstein- 
Barr nuclear antigen 1,  early antigens, and viral capsld antigens. 
These patients showed dramatically elevated titers of serum anti- 
bodies against early antigens (range 160 to >640). 
Cells 
PBL and SFL were maintained in RPMI  1640 supplemented 
with 10% human serum, 1 mM L-glutamine (hereafter referred to 
as culture medmm), and recombinant IL-2 (100  IU/ml). T  cell 
clones were  isolated and resumulated once a  month as follows. 
Synovlal T  cells (either total or sorted by means of TCR BV re- 
Non-specific mAb) were seeded at 0.3 cells/well and cultured in 
culture medium supplemented with  IL-2  (100  IU/ml), purified 
PHA (leucoagglutinin, 0.5 Ixg/ml) and irradiated (30 Gy) alloge- 
neic feeder cells. Such culture conditions allow the growth of vir- 
tually all T  cells and do not introduce any bias in the T cell reper- 
toire, as demonstrated by flow cytometry analysis using TCR BV 
region-specific mAb and by analysis of TCR CDR3 length dis- 
tribution (22;  Llm, A., M.A. Peyrat, and M. Bonneville, unpub- 
lished data). Coreceptor phenotype, TCR features, and HLA re- 
stnction of T  cell clones are detailed elsewhere (20) and summarized 
in Table 1. 
Expression  Cloning of T  Cell Antigens 
Construction of the cDNA Library.  Poly(A)  +  KNA  was  prepared 
from patient 1 BLC using an mRNA purification kit (Pharmacla 
Fine Chemicals, Plscataway, NJ).  cDNAs were synthesized using 
a Zap-cDNA synthesis kit (Stratagene Inc., La Jolla, CA). BstXI 
adaptators  (Invltrogen, San Diego, CA) were hgated to the cDNAs. 
After size fractionauon, cDNAs were  cloned into pcDNA3  (In- 
vitrogen) digested with BstXI. Recombinant plasmids were elec- 
troporated  into Escherichia coli X1-1  and selected with ampicilhn 
(50 Ixg/ml). The library was divided into 288 pools of 200 cDNA 
clones. Each pool was amplified to saturation, and plasmid DNA 
was extracted by the alkaline lysis method. 
Transfection of COS Cells.  Transfection was performed by the 
DEAE-dextran-chloroquine  method  as  described  (23,  24).  In 
brief,  1.5  ×  104 COS cells were transfected with 100 ng ofplas- 
mid containing the relevant HLA DNA and 100 ng of a pool of 
the cDNA library. The genomic HLA-A*0101, which was kindly 
provided by Dr. J. Girdlestone (Medical Research Council, Cam- 
bridge, UK), was cloned into pcDNA3.  Genomic HLA-A*0201 
DNA, HLA-A*2401 cDNA, and HLA-A*0301 were kindly pro- 
vided by T. Boon (Ludwig Institute, Brussels, Belgium). HLA- 
A*0201 was cloned into pSV2 vector, HLA-A*2401 and A*0301 
were in pcDNA3.  The cDNA HLA-B*3501, which was kindly 
provided by Dr. L. Satz (Laboratory of Immunogenetics, Hospital 
de  Clinicas Jose  de  San Martin,  Buenos Aires,  Argentina), was 
cloned into pcDNA3.  HLA-B*4002 and Cw*0102 were  cloned 
from the B  cell cDNA library. Transfectants were then tested for 
their ability to stimulate TNF production by T  cells  (see below). 
Each positive pool was subcloned into 800-1,600 bacteria, which 
were each tested for their ability to trigger T  cell clone TNF re- 
lease  after  expression  m  COS  cells  cotransfected with  relevant 
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HLA DNA. Positive clones were sequenced by the dideoxy chain 
termlnauon method. 
T Cell Stimulation Assay.  T  cells  were  added  to  COS  cells 
24--48  h  after  transfection,  and culture  supernatants were  har- 
vested 6-18 h later and tested for TNF content by measuring cul- 
ture supematant cytotoxicity to WEHI164 clone 13 in a colori- 
metric assay (25). 
Production of Truncated BMLF1 or BZLF1 cDNA.  Truncated 
BMLF1 cDNA fragments, generated by partial digests, were cloned 
into pcDNA3, pcDNA3 vector was also  used to clone a  140-bp 
fragment after PCR amphfication of the ASaclI BMLF1 fragment 
with ohgonucleotides BM1 (5'-GCGGATCCGCCACCATG-3'), 
introducing a BamHI site for cloning and an internal ATG, and 
SP6  (5'-ATTTAGGTGACACTATAG-3'). Truncated  BZLF1 
cDNA fragments, generated by partial digests,  were  cloned into 
pcDNA3. 
Peptide Assays 
Lyophilized  peptides  (Chiron  Mimotopes  Corp.,  Victoria, 
Australia)  were  dissolved at  20  mg/ml in DMSO,  diluted at  2 
mg/ml in 10 mM aceuc acid, and stored at -80°C. In cytotox]c- 
ity assays, 2.5 ×  104 51Cr-labeled A2.10 T  cells were incubated m 
the presence of peptides at various concentrations, and SlCr re- 
lease was measured after 3 h  at 37°C. Percentage of specific lysls 
was calculated as described in (22).  In TNF release assays, 2.5  × 
10  4 T  cells  were  incubated for 5  h  with the peptldes at vanous 
concentrations, and the amount of TNF released in the superna- 
tant was estimated by the WEHI 164 cytotoxiclty assay. 
T  Cell Cytotoxicity  and Proliferation Assays 
Both  kinds of assays were  performed as previously described 
(22).  In brief, cytotoxic activity ofT cell clones toward BLC was 
measured by a standard 4-h SlCr-release assay at two E/T ratios. 
T cell clone cytolytic potential was estimated by lectin-dependent 
kilhng of target cells (i.e., by evaluating T  cell cytotoxic activity in 
the culture medium supplemented with 0.5 Ixg/ml of purified PHA 
[leucoagglutmln]). Proliferative activity of responder T  cells  was 
esumated after a 48-h culture of 10  4 responder cells  with 2.5  × 
104 irradiated BLC m  100  txl of culture medium supplemented 
with rlL-2, followed by an overnight pulse with 0.5 IxCI of triti- 
ated thymidine. 
COS  Transfection  Assays  Using Polyclonal  T  Cell Lines 
Patients' PBL, SFL, or SML were cultured for 15 d in culture 
medium  supplemented with  rlL-2  and leucoagglutmin. Under 
such culture condiuons, no TCR repertoire skewings were intro- 
duced, as suggested by comparative analysis of TCR BV CDR3 
length distribution of some synovial samples before and after cul- 
ture (Llm, A., M.A. Peyrat, and M. Bonneville, unpublished ob- 
servations).  After washing, cells were maintmned for 7 d in culture 
medium with rI1-2  but without lectin, to  decrease  spontaneous 
TNF release. TNF secretion in culture supematant was then esti- 
mated as described above, after incubating for 6 h varying num- 
bers of responder T  cells (from 103 to  105) together with conflu- 
ent  COS  cells  transfected 24  h  earlier with  HLA  and/or EBV 
cDNAs. 
Results 
We recently showed that a large fraction ofsynovial T  cell 
clones derived  from  two  patients  (hereafter  referred  to  as 
patients 1 and 19) proliferated in vitro when exposed to au- A  B  T~ ~  Figure  1.  Idenuficatlon  of 
T cell  HLA-  cDNA  ATG  m~,  s,~,  the  antigenic  peptlde recog- 
A2.10  A'0201 BMLF1  •  ~  I  +  nized  by  the  synowal T  cell 
n~,  clone A2.10. (A) BMLF1 recog-  ÷  h  f  __ 
nltIOn  by  the  HLA-A*0201- 
"-""  restricted  T  celt clone A2.10 
©  I  + 
÷  ÷  A2.10  T  cells were added  to 
ATG~  N  d  N10O  ~  +  COS  cells  transfected  with 
+  +  BMLF1  cDNA  and  HLA- 
A*0201 DNA, or with each of 
+  ÷  +  these  DNA  TNF  production 
t  p  ,  ,  ,  was assessed after a 6-18-h lncu- 
I0  20  30  40  50 
TNF  release  (pg/ml)  batlon  as  described  (18).  (B) 
Mapping  of  the  BMLF1  se- 
quence coding for the antlgemc 
C  D  peptlde  recognized  by  clone 
'°  ~  A  '°°  ~  A2.10. BMLF1 cDNA fragments 
~  E  were cloned Into pcDNA3 and 
//  tested for their ability to reduce 
i  ~  A2.10  TNF  production after 
transfectIon Into COS  cells to- 
m  ~  gether  with  HLA-A*0201.  +, 
"  2~  A2.10 TNF release >22 pg/ml. 
~,0  Z  -  A2.10 TNF release <1  pg/ 
ml  (C) Inducnon of A2.10 clone 
o  ,  ,  ~  o-,  .....  autocytotoxlclty  by  synthetic  o  2s  so  7s  Ioo  2s  so  7|  Ioo 
Peptide concentration (nM)  Peptide concentration (nM)  BMLF1 peptides. 10 pept]des (5 
9-mers,  4  10-mers, and  I  11- 
mer) encoded by the 140 bp fragment defined  m B and containing  consensus  binding "anchor" res]dues to HLA-A*0201 were synthesized Significant  T 
cell clone lysls  was observed with peptlde GLCTLVAML  but with none of the 9 other peptIdes tested. Data obtained with pepude TLVAMLEETI  are 
shown as a negative  example. (D) Induction of A2.10 clone TNF release by synthetic  BMLF1 peptldes. Peptide GLCTLVAML  but none of the 9 other 
peptides tested snmulated  production of TNF by clone A2.10. Peptlde TLVAMLEETI  is shown as a negative  control. 
tologous BLC (20). The fact that autologous BLC-reactive 
clones were found in both CD4 + and CD8 + T  cell subsets 
suggested  that  this  reactivity was  a  general feature  of sy- 
novial T  cells, regardless of their coreceptor phenotype (20). 
In an attempt to establish the fine specificity of these cells, 
cDNAs  from  a  patient  1  BLC  hbrary were  screened for 
their ability to trigger TNF production by synovial T  cell 
clones after transient cotransfection into COS cells together 
with DNAs encoding the appropriate MHC allele (23, 24). 
Because this approach is well suited for cloning MHC class 
I- but not class II-restricted Ags (23), this analysis focused 
on the characterization of Ag recognized by CD8 + syno- 
vial T  cell clones. 
Recognition of the EBV Transactivator BMLF1 by the Syno- 
vial T  Cell Clone A2.10.  A  T  cell  clone from  patient  1, 
A2.10,  recognizing autologous BLC  in an HLA-A*0201- 
restricted fashion  (Table  1),  was  analyzed first.  Using the 
COS transfection approach (23, 24), we identified 2 out of 
270 cDNA pools that induced TNF production by clone 
A2.10  after cotransfection with HLA-A*0201  DNA.  Out 
of 800 clones derived from one positive pool, one 1,591-bp 
cDNA induced TNF production by A2.10 cells when co- 
transfected with HLA-A*0201 DNA (Fig.  1 A). Its sequence 
was identical to that of an EBV gene, BMLF1, encoding a 
439-amino acid protein expressed during the early stage of 
the virus rephcative cycle (26, 27). Because of the transacti- 
vating properties of the BMLF1  product (26), this protein 
could upregulate the expression of endogenous Ag recog- 
nized in turn by the synovial T  cell clone rather than being 
recognized itselE To address this question, truncated BMLF1 
cDNAs were tested for their ability to activate A2.10 TNF 
release  after  cotransfection  with  HLA-A*0201  DNA.  A 
BMLF1  region  encoded  by  a  HinclI/SacH  140-bp  se- 
quence was shown to be stimulatory (Fig.  1 B).  Of several 
peptides located in this region and synthesized on the basis 
of their consensus bmding capacities to HLA-A*0201  (28), 
only the  nonapeptide  GLCTLVAML  (amino  acids  259- 
267)  induced autocytotoxicity and TNF release by A2.10 
cells (Fig. 1,  C  and D). This formally demonstrates a classic 
MHC-restricted recognition of the BMLF1 protein. 
Recognition of the EBV Transactivator BZLFI by the Syno- 
vial T  Cell Clone A 17.11.  The antigenic specificity of an- 
other synovial T  cell clone from patient 1, A17.11, which 
recognized autologous BLC in an HLA-Cw*0102-restricted 
fashion (Table 1), was then studied. Because this clone did 
not react  with  COS  cells cotransfected with BMLF1  and 
HLA-Cw*0102  cDNAs,  the  cloning  strategy  described 
above  was  applied  once  again  (23).  One  cDNA,  which 
conferred recognition of COS  cells by A17.11  cells after 
cotransfection with HLA-Cw*0102 DNA (Fig. 2), contained 
a  753-bp  cDNA  insert  encoding BZLF1,  another  early 
EBV protein with transactivating  properties (29). 
Dominant Response  of Synovial  T  Cells from  Patient  1 to 
EB V Transactivators.  We then tested the reactivity toward 
BMLF1-  or  BZLFl-transfected COS  cells  of the  whole 
panel of BLC 1-reactive CD8 + synovial T  cell clones with 
a  known  HLA  restriction  element  (A*0201,  B'4002,  or 
Cw*0102) and expressing distinct T  cell receptors (Table 1). 
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Figure  2. 
÷ 
I  I  I 
10  20  30 
TNF  releue  (pg/ml) 
BZLF1 recogniuon by the HLA-Cw*0102-restncted  T cell 
clone A17.11. TNF released by T cell clone A17.11 was measured after 
incubataon with COS cells transfected with BZLF1 and HLA-Cw*0102 
cDNA or with each of these cDNA. The experimental protocol is the 
same as described m the legend to Fig. 1. 
Whereas one other clone reacted with BZLF1 in the con- 
text of HLA-Cw*0102 (clone A17.10, Table 2), most T  cell 
clones recognized BZLF1  in the  context of HLA-B*4002 
(representative data shown in Fig. 3 A  and summarized in 
Table 2). The characterization of T  cell clones recognizing 
BZLF1 in the context of HLA-B*4002, for which peptide 
anchor motifs are  well defined (28),  allowed us to  deter- 
mine whether, similarly to BMLF1, this transactivator was 
recognized as a peptidic antigen presented by MHC prod- 
ucts. In support of this, BZLF1 cDNA fragments able to trig- 
ger TNF production by T  cell clone A14.7 after cotrans- 
fection with HLA-B*4002 DNA into COS  cells could be 
defined (Fig.  3  B),  and a  synthetic peptide located in the 
stimulatory BZLF1  region  was  shown  to  trigger  T  cell 
clone autocytotoxicity and TNF release (Fig. 3,  C and D). 
That there is  an enrichment for T  cells reacting against 
BZLF1/BMLF1  antigens  within  the  inflamed joints  of 
patient 1 is supported by two lines of evidence. First, T  cells 
expressing TCR-[3  chains with V[3/J[3  combinations and 
lengths identical to those expressed by EBV-reactive T  cell 
clones accounted for "°30% of synovial T  cells, but only a 
minute fraction of peripheral blood T  cells from patient 1 
(Table  1).  Second,  TNF  production by short-term  cul- 
tured synovial fluid and peripheral blood T  cells from pa- 
tient 1 induced by COS cells transfected with either HLA- 
A*0201, B'4002, or Cw*0102 DNAs together with either 
BZLF1  or  BMLF1  cDNAs  differ  dramatically: compare 
the  amounts of TNF released by synovial as  compared to 
peripheral blood T  cells after exposure to COS cells trans- 
fected with BMLF1  and A*0201  DNAs (Fig.  4,  upper left) or 
BZLF1  and B'4002  DNAs  (Fig.  4,  lower middle).  Signif- 
icantly, dominant responses to BZLF1/B*4002 and BMLF1/ 
A*0201  were  seen with synovial membrane-derived lym- 
phocytes recovered 27 mo after the first sample (Fig. 4), in- 
dicating that these reactivities are common and long-lasting 
features of synovial lymphocytes derived from patient 1. 
T  Cell Responses  to BMLF1/BZLF1  in Other Chronic RA 
Patients.  An enrichment for autologous BLC-reacfive T  cells 
within the  synovium in another chronic RA patient (pa- 
tient 19)  was suggested by the fact that unlike PBL clones, 
4  of 12  randomly chosen  CD8 ÷  synovial clones derived 
Table 2.  TNF Responses of Synovial T Cell Clones  from 
Patient I to BMLF1- or BZLFl-transfected  COS Cells 
TNF release 
BZLF1 
BMLF1 
T cell clone  A*0201  B'4002  Cw*0102 
pg /ml 
A2.10  44.5  -  - 
A2.19  -  45.8  - 
A2.3  -  37.4  - 
A2.8  -  39.5  - 
A2.1  -  18.6  - 
A2.21  -  3O.8  - 
A2.4  -  1.2  - 
A14.11  -  6.0  - 
A14.7  -  39.3  - 
A22.28  -  13.0  - 
A22.19  -  37.5  - 
A22.13  -  25.0  - 
A22.32  -  25.0  - 
A22.34  -  25.0  - 
A22.18  -  20.0  - 
Al7.10  -  -  20.0 
Al7.11  -  -  13.6 
TNF producuon by T cell clones was estimated after incubation with 
COS cells tranfected with rather BMLF1 or BZLF1 cDNAs and either 
HLA-A*0201, -B'4002,  or -Cw*0102 DNAs. Shown are the results 
obtained with HLA/Ag cornblnanons ymlding  sxgnificant  TNF produc- 
non (0.5 pg/ml) by any of the T cell clones tested. -, TNF secrenon 
<(I.5 pg/ml. 
from this patient reacted against the  autologous BLC  (20). 
Because the HLA restriction of these clones was established 
(3 clones were HLA-B*35 restricted and 1 clone was HLA- 
A'24 restricted)  (Table 1), we could evaluate their reactiv- 
ity  toward  BZLF1  and  BMLF1  after  transfection of the 
corresponding cDNA into COS cells together with HLA- 
A'2401  or  -B'3501  cDNAs.  Whereas  the  HLA-A*24- 
restricted clone reacted against neither BMLF1 nor BZLF1 
(data  not  shown),  all  the  HLA-B*35-restricted  T  cell 
clones turned out to recognize BZLF1 (Table 3). 
T  cell responses to BMLF1 and BZLF1 were also studied 
at the polyclonal level in patient 19  and in several HLA- 
A*02 + chronic RA patients. In agreement with the above 
results, a clear TNF response was detected when incubating 
short-term cultured synovial T  cells from patient 19 with 
HLA-B*3501/BZLF1-transfected COS cells (Fig. 5, right). 
Moreover, comparison of the amounts of TNF released by 
PBL  and  SFL  under these  assay  conditions strongly sug- 
gested an enrichment within the synovium for T  cells reac- 
tive against BZLF1 in patient 19  (Fig. 5). Sigmficant TNF 
1795  Scotet et al. A 
T cell  .  HLA.  cDNA 
A14.7  B'4002  BZLF1 
+ 
4.  ÷ 
4-  4. 
4.  4-  4. 
I  i  i  i  I 
o  IO  20  8o  40  5o 
TNF release (~ml) 
C 
4O 
~,o 
t  l 
Ioo  i~ 
Peptide  concentration  (nM) 
B 
ATG  P~u  I  A~l  I  ~  I  I&lc  I 
•  I  I  r  I  I 
P,  ui 
b 
Avs  I 
©  A 
d  :  I 
•  ml  A 
~ioo  i~ 
T~ 
÷ 
÷ 
D 
Ioo 
i  J  J 
2oo  4o0  eoo  8oo  tooo 
PepUde concentration  (nM) 
release 
Figure  3.  Identification  of  the 
BZLF1  peptlde recogmzed by the T 
cell clone A14.7.  (A) BZLF1 recogni- 
tion by the HLA-B*4002-restncted  T 
cell  clone  A147.  TNF  release  by 
clone A14.7 was measured after incu- 
bation with COS cells transfected with 
BZLF1  and  HLA-B*4002  cDNA  or 
with each  of these  cDNA.  (B)  Map- 
ping of the BZLF1 sequence  coding 
for  the  antigenic  peptlde  recognized 
by clone A14.7. For experimental pro- 
cedures,  see  Matenals  and  Methods 
and legend to Fig. 1. (C) Induction of 
A14.7  clone autocytotoxlclty  by syn- 
thetic BZLF1 peptldes.  One  peptade 
(SENDP,.LRLL) encoded by the 90- 
bp PstI/HinclI fragment  defined in B 
and containing  consensus binding an- 
chor  residues  to  HLA-B*4002  (28) 
was synthesized. T cell clone cytotox- 
1city was estimated after incubation for 
3 h at 37°C in the presence of either 
the above peptlde or an irrelevant one 
(RAKFKQLL).  (D)  Induction  of 
A14.7 clone TNF release by synthetic 
BZLF1 peptldes. TNF productaon was 
estimated after a 3-h Incubation  with 
peptlde SENDP,.LRLL. 
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Figure  4.  TNF  responses of PBL,  SFL, and  SML from patient  1 to 
BMLF1-  or  BZLFl-transfected COS  cells. Short-term-cultured PBL, 
SFL, and  SML were incubated  with COS cells transfected with either 
responses to  COS  cells transfected with HLA-A*0201  and 
either BMLF1  or BZLF1  cDNA  were also readily detected 
within short-term-cultured synovial T  cells derived from 4 
out of 9  HLA-A*02 patients (patients 1, 3, 5, and 6)  (Fig. 5, 
/eft,  and data not shown). Similarly to patient 1,  an ennch- 
ment  for  HLA-A*02/BMLF1  reactive  cells  within  the 
joints of patient 6  was seen when comparing TNF  produc- 
tion obtained with PBL and SFL. Taken together, these re- 
suits suggest that T  cells reactive against these EBV transac- 
tivators are frequently expanded during chronic tLA. 
Evaluation of Cytolytic Activity of Synovial  T  Cell Clones to- 
ward BLC.  Because  BLC  are  known  to  be  latently  in- 
fected by EBV, the recognition by BLC-reactlve T  cells of 
BMLF1  or BZLF1, which are expressed exclusively during 
the virus lytic cycle, was rather unexpected and prompted 
us to analyze further the funcuonal behavior of these T  cells 
toward BLC. Although synovial T  cell clones strongly pro- 
BMLFI  cDNA together with HLA-A*0201  (upper /eft), B'4002  (upper 
middle), or Cw*0102 (upper right), or BZLF1 cDNA together with HLA- 
A*0201 (lower  left), B'4002 (lower middle), or Cw*0102 DNA (lower right). 
Lymphocytes were added at three concentrations  to COS cells 1 d after 
transfecuon, and TNF release was measured  1 d later. Specific TNF re- 
lease was calculated by subtracting values obtained with COS cells trans- 
fected with BZLF1  or BMLF1 and  an irrelevant  HLA  DNA (A*0101) 
from those obtained under the above conditions  Note that dominant re- 
sponses  to  BMLFI/A*0201  and  t3ZLF1/B*4002  were  observed  with 
both SFL and SML recovered 27 mo later. There was at least a 100-fold 
difference (on a per cell basis) between the amounts of TNF released by 
SFL versus PBL after exposure to BMLF1/A*0201- and BZLF1/B*4002- 
transfected COS cells. Weak but significant responses to BMLF 1/B'4002 
(upper middle), BZLF1/A*0201  (lou,er left), and  BZLF1/Cw*0102  (lower 
right) were obtained with SFL and/or SML. 
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Patient  19 to BMLF1- or BZLFl-transfected COS Cells 
T  cell clone  (-) 
TNF release 
B'3501 
BMLF1  BZLF1 
pg/ml 
B2  -  -  26.5 
B3  -  -  32.3 
B4  -  -  27.4 
TNF production by T  cell clones was estimated  after incubation with 
COS cells transfected  with HLA-B*3501 cDNA and either BMLF1 or 
BZLFt cDNAs. -, TNF secretion <1.0 pg/ml 
Table 4.  Cytolytic Activity of Synovial  T  Cell Clones from 
Patient  1 toward BLC Triggering their Proliferation 
Cytotoxicity 
BLC  BLC +  lectm 
Specific 
T  cell clone  20:1  5:1  20:1  5:1  proliferation 
A2.3  3  1  67  54  26 833 
A2.10  2  0  68  55  12 457 
A2.19  6  6  70  72  48 129 
A14.7  7  6  88  70  70 374 
A17.10  4  4  46  35  66 877 
A17.11  3  3  74  68  7 795 
A22.19  5  4  81  83  61 656 
A22.28  10  9  79  61  28 196 
liferated when  exposed  to  BLC  expressing the  appropriate 
HLA allele (Table 4; and reference 20),  none of them were 
able to kill to detectable  levels BLC which  otherwise  trig- 
gered  their  proliferation  (Table  4  and  data  not  shown). 
This could not be explained by a lack of lyric potential be- 
cause  (a)  these clones efficiently lysed BLC in the presence of 
lectin  (Table  4),  and  (b)  addition  of appropriate  synthetic 
peptides  to  synovlal T  cell clones resulted in efficient pep- 
tide  self presentation  and  autocytotoxicity  (Figs.  1  and  3). 
Actually, this peculiar behavior is most probably  explained 
by the T  cell clone's fine specificity. Indeed,  although BLC 
are known  to  express  predominantly  EBV latent  proteins, 
rare  cells supporting a  fully productive EBV infection have 
BMLFll  A* 0201  BZLFI/B'3501 
7 
E 
5 
u.  3 
o  w- 
Q. 
u)  0 
7' 
5 
4 
3' 
2 
1 
I  !  0 
PBL  SFL 
/ 
Figure 5.  TNF responses ofsynovlal T cells derived from HLA-B*35 ÷ 
and HLA-A*02 + chromc RA patients to BMLF1- or BZLFl-transfected 
COS cells 105 short-term-cultured  synovlal T cells and PBL denved from 
nine HLA-A2  + RA patients and one HLA-B*35 + patient were incubated 
with COS cells transfected with HLA-A*I)201 and BMLF1 or with HLA- 
B'3501  and BZLF1  DNA, respectively. Specific TNF release was calcu- 
lated by subtracting the amounts of TNF secreted in the presence of COS 
cells transfected with an irrelevant  HLA DNA (HLA-A*0301) and either 
BZLF1  or BMLF1 from those obtained  with the restricting  HLA DNA. 
Significant responses were observed m 5 patients  (patients  1, 3, 5, 6, and 
19). Shown are the results obtained  with three HLA-A*02 patients  (pa- 
tients 3, 5, and 6) (left) and with the HLA-B*35 pauent (patient 19) (right). 
For patient 3, results obtained with PBL were not interpretable because of 
a high spontaneous TNF release 
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Cytotoxlc activity of synovlal  T  cell clones  toward  autologous BLC 
(no.  1) was assessed at 20:1 and 5:1 E/T ratios. T cell lyuc potential was 
calculated  by estimating  target  killing in the presence  of punfied PHA 
(leucoagglutlmn)  (0.5 ~g/ml). Results are  expressed  as percentage of 
specific lysis. Tritiated thymldme uptake  of synovial T  cell clones was 
estimated  after  a 2-d coculture with irradiated  BLC. Results  are  ex- 
pressed as (cpm of T  cells +  BLC)  -  (cpm of T  cells +  cpm of BLC 
alone). Values correspond to means of duphcate  counts (for cytotoxlclty 
assays) or mphcate counts (for proliferation assays). 
been  detected  in  most  BLC  lines  studied  (30).  Such  cells 
could  efficiently  trigger  proliferation  of T  cell  clones  di- 
rected against lytic proteins,  although their lysis by the cor- 
responding CTL might not be detectable in standard cytotox- 
icity assays. 
Discussion 
We  study here the fine specificity of synovial T  cells de- 
rived from  several  chronic  P,-A patients.  Our  results  indi- 
cate  that  in  two  patients,  a  large  fraction  of T  cell clones 
derived from synovial fluid and synovial membranes  of in- 
flamed joints reacts  against  two EBV transactivators,  BMLF1 
and  BZLF1.  Moreover,  responses  against  these  EBV  pro- 
teins  were  evidenced within  short-term-cultured  synovial 
T  cells derived from several other RA  patients.  These  ob- 
servations  raise  questions  regarding  (a)  the  mechanisms 
governing  T  cell  recruitment  to  the  synovium  during 
chronic  RA,  (b)  the  implication  of EBV  in  chronic  RA 
pathogenesis and the possible pathogenic role of EBV-reac- 
tive T  cells,  (c)  the possible  dominance  of anti-EBV T  cell 
responses  in  RA  patients  toward  a  specific set  of proteins, 
and  (d)  the  general significance  and  consequences  of EBV 
transactivator recognition by T  cells. 
Regarding  the  first  issue,  it  has  been  widely  accepted 
that  synovium infiltration by T  cells in chronic RA  results 
from  nonspecific  trapping  of T  cells,  e.g.,  in  response  to chemotactic factors released during the inflammatory reac- 
tion (19, 31). Our results show that a large fraction ofsyno- 
vial T  cells from two chronic RA patients recognizes a re- 
stricted set of EBV antigens, thus demonstrating that at least 
in some patients,  T  cell recruitment  to the synovium is an 
active Ag-driven process. Although  conflicting results have 
been  obtained  regarding  the  presence  or  absence  of the 
EBV  genome  in  synovia (32-34),  it is possible that EBV- 
reactive  T  cells  are  expanded  locally  after  recognition  of 
EBV-infected  cells  within  the  joint.  Alternatively,  EBV 
could trigger cross-reactwe T  cell responses against cellular 
proteins  expressed  in  target  organs.  In  this  regard,  several 
reports have described shared sequences between MHC  al- 
leles linked to increased RA susceptibility and EBV glyco- 
proteins  (35-38). 
With respect to the second issue, implication of EBV in 
RA  was first proposed  several years ago,  based  on  several 
clinical  studies  demonstrating  increased  EBV  loads  and 
anti-EBV  Ab  titers  in  the  sera  of RA  patients  (39,  40). 
However,  since  no  evidence  for  increased  anti-EBV  re- 
sponses in RA lesions was provided, the physiopathological 
significance of these findings has remained controversial.  In 
particular,  the possibility that these clinical observations re- 
flected  a  general  alteration  of immune  responses  due  to 
chronic inflammation rather than an active participation  of 
EBV infection in RA pathogenesis  could not be ruled out. 
In this regard, our demonstration that EBV-reactive T  cells 
are enriched within  the joints of chronic 1LA patients pro- 
vides,  for  the  first  time,  a  direct  link  between  EBV  and 
RA.  Furthermore,  the fact that these patients showed con- 
comittantly high anti-EBV Ab titers suggests that increased 
anti-EBV  serological responses previously found in a large 
fraction  of chronic  RA patients  (39,  40)  is associated with 
specific  activation  of EBV-reactive  T  cells  within  the  le- 
sions. Although  our results suggest that EBV-reactive T  cells 
in RA lesions are very likely to be pathogenic, it remains to 
be established definitively whether these cells exert harmful 
effects, for example,  through  direct  cytotoxicity or release 
of inflammatory  cytokines  activating  T  cell-independent 
joint erosion (e.g., mediated by synoviocytes) (19). Analysis 
of the in vivo behavior of these cells (e.g., in SCID/human 
models) will certainly help resolve these issues. 
Whether  or not anti-EBV  responses in RA are directed 
against a restricted set of antigens is another interesting ques- 
tion.  At present,  a  comparison  of EBV responses between 
RA and non-RA individuals remains difficult, because none 
of the studies performed to date have really addressed T  cell 
responses against EBV lytic proteins in non-RA EBV-mfected 
individuals  (30).  Moreover,  the  fact that  some BLC-reac- 
tive  synovial T  cell  clones  do  not  respond  to  BMLF1  or 
BZLF1  in COS transfection assays strongly suggests recog- 
nition  of a  larger  set  of EBV  proteins  by  ILA  patient- 
derived T  cells. Despite this, biased anti-EBV responses to- 
ward proteins  of the virus rephcative cycle in RA patients 
is  strongly  suggested  by  the  following  observations.  As 
mentioned  before,  EBV  is known  to enter the  lytic  cycle 
only  in  a  minority  of cells  in  BLC  cultures.  Therefore  a 
dominant  response  against proteins  expressed  at that  stage 
could explain both the decreased cytotoxic responses against 
autologous  BLC  frequently  observed  in  RA  patients  (41, 
42) and our inability to detect significant killing of BLC by 
synovial CTL in standard cytotoxicity assays (Table 4).  It is 
noteworthy  that  this  pecufiar  behavior  could  also  explain 
why synovial CD8 + T  cell responses to EBV have not been 
detected  before,  because  specificity of these  cells is classi- 
cally established through cytotoxicity assays. 
Beyond the field of autoimmunity, these observations pro- 
vide new insights  into  the fine specificity of the  anti-EBV 
T  cell response  and  the immune  control  of EBV reactiva- 
tion,  because they provide the first clear-cut evidence that 
the  BZLF1  and  BMLF1  EBV-transactivating  proteins  can 
be targets for CD8 + T  cells. T  cell recognition of such pro- 
teins has been suspected in several EBV-linked pathological 
situations  (e.g.,  acute  infectious  mononucleosis,  nasopha- 
ryngeal  carcinoma,  EBV reactivation  in immunodepressed 
patients)  during which  serological Ab titers against BZLF1 
product  and other early antigens are significantly increased 
(for review  see  reference  30).  However,  technical  limita- 
tions have hampered direct  analysis of T  cell responses  di- 
rected against EBV lytic antigens.  The physiological signifi- 
cance  of BZLF1/BMLF1  recognition  by  T  cells  can  be 
inferred  from  the  function  of these  proteins  during  virus 
replication.  BZLF1  is  the  first  gene  expressed  draring  the 
immediate  early  stage  of the  EBV  lytic  cycle,  and  it  is 
thought  to  turn  on  expression  of many  other  immediate 
early genes (43). BMLF1  is a delayed immediate early gene 
with promiscuous transactivating properties that acts syner- 
gistically  with  BMLF1  and  another  EBV  transactivator, 
B1LLF1,  in in vitro  assays (43).  It is therefore  likely that 
T  cell  responses  against  these  two  key  transactivators  of 
EBV lytlc infection play a  central  role in  controlling  virus 
spreading  under  physiological  and  pathological  situations. 
With  the  recent  development  of murine  models  allowing 
in vivo analysis of anti-EBV  human  T  cell responses  (44), 
this hypothesis can now be tested. 
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